NeoGenomics Stock Price, News & Analysis (NASDAQ:NEO) $18.48 -0.61 (-3.20%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$18.34▼$18.9750-Day Range$11.67▼$19.5152-Week Range$8.70▼$20.54Volume716,485 shsAverage Volume972,525 shsMarket Capitalization$2.36 billionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media NeoGenomics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside2.8% Upside$19.00 Price TargetShort InterestBearish4.93% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.68Based on 2 Articles This WeekInsider TradingSelling Shares$49,083 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.35) to ($0.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.30 out of 5 starsMedical Sector889th out of 948 stocksTesting Laboratories Industry1st out of 1 stocks 1.4 Analyst's Opinion Consensus RatingNeoGenomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, NeoGenomics has a forecasted upside of 2.8% from its current price of $18.48.Amount of Analyst CoverageNeoGenomics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.93% of the outstanding shares of NeoGenomics have been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in NeoGenomics has recently increased by 2.11%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNeoGenomics does not currently pay a dividend.Dividend GrowthNeoGenomics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NEO. Previous Next 1.8 News and Social Media Coverage News SentimentNeoGenomics has a news sentiment score of -0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NeoGenomics this week, compared to 3 articles on an average week.Search Interest17 people have searched for NEO on MarketBeat in the last 30 days. This is an increase of 467% compared to the previous 30 days.MarketBeat Follows6 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeoGenomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,083.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of NeoGenomics is held by insiders.Percentage Held by Institutions91.36% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeoGenomics are expected to grow in the coming year, from ($0.35) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeoGenomics is -24.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeoGenomics is -24.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoGenomics has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NeoGenomics Stock (NASDAQ:NEO)NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.Read More NEO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NEO Stock News HeadlinesDecember 5, 2023 | finance.yahoo.comNeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy ResponseNovember 29, 2023 | americanbankingnews.comStock Traders Purchase High Volume of NeoGenomics Call Options (NASDAQ:NEO)December 6, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 14, 2023 | finance.yahoo.comNeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare ConferenceNovember 13, 2023 | finance.yahoo.comWall Street Analysts See a 28.17% Upside in NeoGenomics (NEO): Can the Stock Really Move This High?November 8, 2023 | markets.businessinsider.comNeoGenomics’ Strong Performance and Growth Potential: Reasons Behind Analyst’s Buy Rating and Increased Price TargetNovember 7, 2023 | finance.yahoo.comNeoGenomics reports 3Q revenue up 18%, narrower net loss; boosts year forecastNovember 7, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About NeoGenomicsDecember 6, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 7, 2023 | finance.yahoo.comNeoGenomics, Inc. (NASDAQ:NEO) Q3 2023 Earnings Call TranscriptNovember 6, 2023 | finance.yahoo.comCompared to Estimates, NeoGenomics (NEO) Q3 Earnings: A Look at Key MetricsNovember 6, 2023 | seekingalpha.comNeoGenomics, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 6, 2023 | msn.comNeoGenomics Non-GAAP EPS of $0.00 beats by $0.08, revenue of $152M beats by $10MNovember 6, 2023 | finance.yahoo.comNeoGenomics Reports Third Quarter 2023 ResultsNovember 6, 2023 | finance.yahoo.comNeoGenomics Inc (NEO) Reports 18% Revenue Increase in Q3 2023November 5, 2023 | markets.businessinsider.comHere's what Wall Street expects from Neogenomics's earnings reportNovember 3, 2023 | morningstar.comNeoGenomics Inc NEOOctober 27, 2023 | finance.yahoo.comWall Street Analysts Think NeoGenomics (NEO) Could Surge 35.08%: Read This Before Placing a BetOctober 25, 2023 | msn.comNeoGenomics: Short-Term Upsides Possible, Long-Term Not Supported By Economic ValueOctober 24, 2023 | nasdaq.comMorgan Stanley Maintains Neogenomics (NEO) Equal-Weight RecommendationOctober 24, 2023 | finance.yahoo.comBull of the Day: NeoGenomics (NEO)October 24, 2023 | finance.yahoo.comNeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer PortfoliosOctober 20, 2023 | msn.comGoldman Sachs Maintains Neogenomics (NEO) Buy RecommendationOctober 17, 2023 | msn.comPiper Sandler Maintains Neogenomics (NEO) Overweight RecommendationOctober 17, 2023 | finance.yahoo.comNeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023October 16, 2023 | markets.businessinsider.comWhere NeoGenomics Stands With AnalystsOctober 13, 2023 | finance.yahoo.comNeoGenomics (NEO) Upgraded to Strong Buy: What Does It Mean for the Stock?See More Headlines Receive NEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Testing laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NEO CUSIPN/A CIK1077183 Webwww.neogenomics.com Phone(239) 768-0600Fax239-690-4237Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$19.00 High Stock Price Target$25.00 Low Stock Price Target$17.00 Potential Upside/Downside+2.9%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-144,250,000.00 Net Margins-16.76% Pretax Margin-18.67% Return on Equity-4.95% Return on Assets-2.81% Debt Debt-to-Equity Ratio0.57 Current Ratio6.32 Quick Ratio6.06 Sales & Book Value Annual Sales$509.73 million Price / Sales4.62 Cash FlowN/A Price / Cash FlowN/A Book Value$7.90 per share Price / Book2.34Miscellaneous Outstanding Shares127,470,000Free Float125,809,000Market Cap$2.35 billion OptionableOptionable Beta1.32 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Christopher Michael Smith BSc (Age 60)CEO & Director Comp: $3.52MMr. Jeffrey S. Sherman M.B.A. (Age 57)Chief Financial Officer Comp: $492.31kMr. Vishal Sikri (Age 47)President of Advanced Diagnostics Division Comp: $1.21MMr. Warren Stone (Age 50)President of Clinical Division Comp: $722.79kMs. Cynthia J. Dieter (Age 48)Chief Accounting Officer Mr. Greg SparksChief Technology OfficerMs. Kendra SweeneyVice President of Investor Relations & CommunicationsMs. Alicia Olivo (Age 39)General Counsel & Corporate Secretary Mr. Hutan Hashemi J.D. (Age 44)Chief Compliance Officer Dr. Derek Lyle M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsIndiviorNASDAQ:INDVCertaraNASDAQ:CERTLivaNovaNASDAQ:LIVNTransMedics GroupNASDAQ:TMDXCymaBay TherapeuticsNASDAQ:CBAYView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Sold 40,211 shares on 11/30/2023Ownership: 0.021%Public Sector Pension Investment BoardSold 68,768 shares on 11/22/2023Ownership: 0.124%Graham Capital Management L.P.Sold 19,104 shares on 11/22/2023Ownership: 0.030%Comerica BankBought 64,232 shares on 11/21/2023Ownership: 0.050%Walleye Capital LLCBought 26,912 shares on 11/21/2023Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions NEO Stock Analysis - Frequently Asked Questions Should I buy or sell NeoGenomics stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NEO shares. View NEO analyst ratings or view top-rated stocks. What is NeoGenomics' stock price target for 2024? 11 brokers have issued 1-year price objectives for NeoGenomics' stock. Their NEO share price targets range from $17.00 to $25.00. On average, they predict the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 2.8% from the stock's current price. View analysts price targets for NEO or view top-rated stocks among Wall Street analysts. How have NEO shares performed in 2023? NeoGenomics' stock was trading at $9.24 at the beginning of the year. Since then, NEO shares have increased by 100.0% and is now trading at $18.48. View the best growth stocks for 2023 here. When is NeoGenomics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our NEO earnings forecast. How were NeoGenomics' earnings last quarter? NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Monday, November, 6th. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.05. The medical research company earned $151.95 million during the quarter, compared to the consensus estimate of $142.15 million. NeoGenomics had a negative net margin of 16.76% and a negative trailing twelve-month return on equity of 4.95%. What ETFs hold NeoGenomics' stock? ETFs with the largest weight of NeoGenomics (NASDAQ:NEO) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and iShares U.S. Healthcare Providers ETF (IHF).SPDR S&P 600 Small Cap ETF (SLY). What guidance has NeoGenomics issued on next quarter's earnings? NeoGenomics updated its FY 2023 earnings guidance on Monday, November, 6th. The company provided earnings per share (EPS) guidance of -$0.18--$0.15 for the period, compared to the consensus EPS estimate of -$0.28. The company issued revenue guidance of $585.00 million-$592.00 million, compared to the consensus revenue estimate of $573.19 million. What is Douglas M. VanOort's approval rating as NeoGenomics' CEO? 116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of NeoGenomics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV). Who are NeoGenomics' major shareholders? NeoGenomics' stock is owned by many different institutional and retail investors. Top institutional investors include Brown Advisory Inc. (6.47%), Schroder Investment Management Group (1.97%), Emerald Advisers LLC (1.51%), Northern Trust Corp (1.24%), Emerald Mutual Fund Advisers Trust (1.22%) and Fred Alger Management LLC (1.04%). Insiders that own company stock include Alicia C Olivo, Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Lawrence Martin Weiss, Mark Mallon, Robert J Shovlin, Steven C Jones and William Bonello. View institutional ownership trends. How do I buy shares of NeoGenomics? Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does NeoGenomics have any subsidiaries? The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.Read More This page (NASDAQ:NEO) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.